Afresa: A New Insulin (By the Way, It's Inhaled)

Afresa consists of “Technosphere” particles, which are tiny lattices of crystals that when inhaled into the lungs, dissolve instantly into a liquid.

| Oct 5, 2009

The enthusiasm for inhaled insulin has waned, to say the least, since Exubera was pulled off the market by Pfizer. Following the Exubera debacle, the development of two other inhaled insulins (AIR by Eli Lilly and Alkermes, and AERx by Novo Nordisk) was halted as well.

But please don't consider that the final word on inhaled insulin. There's a new product in Phase III clinical studies, called Afresa, and it may succeed where the others failed. The reason, says its developer, MannKind Corporation, is that it simply mimics the functioning of natural insulin better than injectable insulins. The fact that it happens to be inhaled is just a side convenience, whereas for Exubera, that was the whole point.

Afresa consists of "Technosphere" particles, which are tiny lattices of crystals that form spontaneously from a liquid, but only under acid conditions (pH below 7). Powdered human recombinant insulin is attached to the lattices electrostatically, after which the particles are dried to a powder and loaded into a inhaler device. When the particles are inhaled into the lungs, they encounter a basic (alkali) environment (pH of 7.3 or 7.4), which causes them to dissolve instantly back into a liquid. The released insulin is then transported from the lung alveoli to adjacent capillaries, sending the insulin to the bloodstream very, very rapidly. The remaining liquid is simply voided from the body.

What's critical here is the fact that peak insulin levels are achieved within 12 to 14 minutes after inhalation. This rapid insulin spike, which mimics the natural insulin spike in response to a meal, is what signals the liver to stop releasing glucose during the meal-time period. Even rapid-acting insulin analogs take 30 to 60 minutes just to begin acting after injection, and they typically peak at four hours. Consequently, there is no quick spike to send the signal to the liver, and endogenous glucose production by the liver is suppressed much more slowly.

Rapid-acting insulin analogs also continue to act for a total of eight hours, although natural post-prandial (after-eating) insulin secretion subsides within two to four hours. In fact, only 18 percent of a subcutaneous insulin injection is consumed by the body during a meal. The remainder continues to have an effect, called a tail, long after natural post-prandial insulin would have returned to basal levels. To avoid this tail, which can lead to low blood sugar, patients have two choices. They can either reduce their insulin dose, which prolongs their hyperglycemia, or they can eat snacks to avert potential hypoglycemia caused by the tail's continued action, which leads to weight gain. In contrast to injected insulin, 74 percent of Technosphere insulin is consumed during a meal. Consequently, patients using Afresa have not gained the weight usually associated with insulin use. In some cases, in fact, they have even lost weight.

The reason that injectable insulin is slower to act than Afresa is in part due to the fact that only monomers, or single insulin molecules, can bind to insulin receptors. In solution, however, monomers join together to form hexamers, which consist of six monomers in a single structure. To be used in the body, the hexamers must first dissociate into dimers, or two molecules, and then into monomers. This takes awhile, making injectable insulin slower to be absorbed.  Rapid-acting insulin analogs have been altered to block the formation of hexamers, thereby improving the speed of absorption. However, they still take between 30 and 60 minutes to peak, much slower than the natural post-prandial insulin release. The manufacturing process for Afresa, however, results in monomeric insulin, which can go right to work without taking the time to dissociate from hexamers into monomers.

The force behind Afresa, and MannKind, is Al Mann, a venerable billionaire who has already sunk a good portion of his fortune into Afresa. In 1979, after a series of inventions that led to very lucrative companies, Mann developed an insulin pump which was the genesis of yet another successful company:  MiniMed (now part of Medtronic). In 1997, he learned of an inhaled insulin, created by a firm called Pharmaceutical Discovery, that peaked in only 12 to 14 minutes and had a bioavailability of up to three times that of the other inhaled insulins. Afresa was born, and Mann is determined to see it grow up. Given his track record, the odds are in his favor.

Afresa is in the news again because the results of two Phase III clinical trials have just been presented at the European Association for the Study of Diabetes (EASD) annual meeting in Vienna. The first study shows that Afresa suppresses endogenous glucose production (EGP), which is the production of glucose by the liver, more rapidly than subcutaneous insulin lispro (Humalog) or Exubera. The study of 18 types 2s found that EGP suppression occurred earliest with Afresa, followed by insulin lispro and then Exubera. 

The second study showed that over four years of continuous treatment using Afresa as their only mealtime insulin, adult patients with type 2 diabetes achieved sustained glycemic control reflected by low A1c's, without significant changes in pulmonary function.

* * *



in-Pharma Technologist press release




Click Here To View Or Post Comments

Categories: A1c Test, Blood Sugar, Diabetes, Diabetes, Insulin, Insulin Pumps, Low Blood Sugar, Medications, Medications Research, Novo Nordisk, Type 1 Issues, Type 2 Issues

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12th Annual Product Reference Guide
  • Insulin Syringe Chart
  • Insulin Pen Needles Chart
  • Fast-Acting Glucose
  • Sharps Disposal
  • Blood Glucose Meters Chart
  • Insulin Pumps Chart
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (14)

You May Also Be Interested In...


Posted by SimosR&R on 5 October 2009

This is a great leap for Mannkind!

Posted by Anonymous on 5 October 2009

Al Mann does not pursue a product unless it has a distinct advantage over existing therapies

Posted by Anonymous on 8 October 2009

I'm afraid to inhale insulin into my lungs. Until I see 10 years of test results that confirm no health issues, I would never use it.

Posted by Anonymous on 8 October 2009

Oh needles, no tubing to get in the way (pumps) AND acts in 12 to 14 minutes!! Has my vote (well maybe..we'll have to wait and see what REALLY comes out of this)

Posted by Anonymous on 8 October 2009

Sounds interesting. Still worried about drug delivery through the lungs. Generex's Oral-lyn looks interesting as it's absorbed through the lining of the mouth which leads to much faster absorption and avoids the lung problems of the former Pfizer and other manufacturer products. Its in Phase III trials. Keeping it on my radar. Just received approval from the FDA for patients who cannot use injections.

Posted by Anonymous on 9 October 2009

My dad is a type 2 diabetic and terrified of insulin - doesn't want to do the shots. I can see the potential of this for folks like won't feel like he's taking insulin.

Posted by Ellis2ca on 9 October 2009

The real question to ask is: Do we really NEED an inhalable insulin? Also: how ACCURATE will be the dose? Will we have to learn to BREATHE the powder in correctly, so that it all gets to the lungs? And if we do not, will we have an accurate dose? plus or minus 30% is a huge variation. And what is really so BAD about the injection? It is totally painless, and it is easy to get the dose correct.

Even if this product gets to market, I am NOT INTERESTED for myself. - Ellis2ca

Posted by Anonymous on 9 October 2009

Analog insulin onset is fifteen minutes, peak is one hour and they are dissipated in four hours. Please check facts.

Posted by Anonymous on 9 October 2009

It looks like all the study subjects were Type 2 diabetics. Since they are insulin resistant, small differences in dose would not be dangerous. I can't see how this would work for insulin-sensitive Type 1's. But it sounds very promising for Type 2's using insulin. And for anyone who needs background insulin and not just meal boluses, I guess they would have to continue with their Lantus or pump.

Posted by Anonymous on 9 October 2009

The article does not state the number of Type 1s used in the study, if any. Would be good to see this in the writeup

Posted by Anonymous on 13 October 2009

I agree about accuracy and possible secondary effects of inhaled insulin. I'd rather use syringes with a far better accuracy, than a painless inhalator with +-30 accuracy. Nowadays needles are painless, so I don't need a painless inhalator.

This is clearly how an outsider thinks. Oh poor diabetics who have to use needles. What they don't know is that there are many things to Diabetes than needles. For instance, when you wake up in the middle of the night with 20mg/dl.
Needles are nothing.

Posted by Anonymous on 13 October 2009

What type of price point in afresa looking at? How often would the individual have to get a new "pump" or delivery device? It sounds like it would be the perfect invention for many people I know ... Is there any way to get into the trial group now? Lots of questions ... please try to answer if you can. Thanks.

Posted by Anonymous on 30 November 2009

If only shots were actually totally painless. Unfortunately, the bruises all over my husband's abdomen from doing his 4 shots a day speak a different story. If there's no belly fat, it's much more difficult not to inject into muscle. I can't wait until inahled insulin is back on the market. He loved the Exubera.

Posted by Anonymous on 9 March 2010

I used the exubera inhaled insulin and my bloodsugars were never better. It was life changing after 16 years of shots and finally an insulin that worked that didnt included shots!!! I am praying that they put back something as this new Afresa on the market and give diabetics an option to get away from the swollen sites from the shots! I am looking forward to it!

Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2015 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.